(19)
(11) EP 4 151 737 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
20.12.2023 Bulletin 2023/51

(43) Date of publication:
22.03.2023 Bulletin 2023/12

(21) Application number: 22194343.4

(22) Date of filing: 20.04.2017
(51) International Patent Classification (IPC): 
C12N 15/86(2006.01)
C07K 14/005(2006.01)
 A61K 48/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 2319/03; C07K 2319/74; C12N 2740/16043; C12N 2740/16045; C12N 2760/18222; A61P 35/00; A61K 2039/5158; A61K 2039/5156; C07K 14/7051; A61K 39/0011; C12N 2740/16023; C12N 15/86; C07K 2319/33; C07K 14/005
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 21.04.2016 EP 16305468

(62) Application number of the earlier application in accordance with Art. 76 EPC:
17720053.2 / 3445862

(71) Applicants:
  • Ecole Normale Supérieure de Lyon
    69007 Lyon (FR)
  • Centre National de la Recherche Scientifique
    75016 Paris (FR)
  • Université Claude Bernard Lyon 1
    69100 Villeurbanne (FR)
  • Institut National de la Santé et de la Recherche Médicale (INSERM)
    75013 Paris (FR)

(72) Inventors:
  • COSTA FEJOZ, Caroline
    69007 Lyon (FR)
  • VERHOEYEN, Els
    06300 Nice (FR)
  • COSSET, François-Loïc
    69004 Lyon (FR)
  • BENDER, Ruben
    60327 Frankfurt (DE)
  • BUCHHOLZ, Christian
    60594 Frankfurt (DE)
  • ZHOU, Qi
    Hitchin SG5 1LF (GB)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)

 
Remarks:
This application was filed on 07.09.2022 as a divisional application to the application mentioned under INID code 62.
 


(54) METHODS FOR SELECTIVELY MODULATING THE ACTIVITY OF DISTINCT SUBTYPES OF CELLS


(57) The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain.
The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.